On October 30, 2020, the Board of Directors of Soliton, Inc. appointed Brad Hauser as President, effective on November 2, 2020. In connection with Mr. Hauser's appointment as President, the Board determined that Mr. Hauser was no longer an independent director and Mr. Hauser resigned from the Board's audit committee, compensation committee and nominating and governance committee. On November 2, 2020, Dr. Chris Capelli transitioned to the position of Chief Science Officer and the Board appointed him as Vice Chairman of the Board. In connection with Dr. Capelli's transition, on October 30, 2020, the Company entered into an amendment to Dr. Capelli's amended and restated employment agreement. Mr. Hauser has been a member of the Company's Board of Directors since June 15, 2018. Mr. Hauser served as the Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since ZELTIQ Aesthetics, Inc. was acquired by Allergan in April 2017 until October 30, 2020. Previously, he served as the Senior Vice President of Research and Development at ZELTIQ Aesthetics, Inc. from January 2017 to April 2017 and as its Vice President of Research and Development from July 2015 to January 2017.